Company profile
OPKO Health, Inc.
Pipeline7 assets
- SomatrogonhGH-CTP / NGENLA / Growth hormone receptor / Biologic / EndocrinologyGrowth Hormone Deficiency (Pediatric)ApprovedactiveUSEUJapanGlobalGrowth Hormone Deficiency (Adults)Phase 3activeGlobal
- Calcifediol extended-releaseRayaldee / Rayaldee / Vitamin D receptor / Small Molecule / NephrologySecondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (Hemodialysis)Phase 2activeUS
- MDX2004MDX2004 / CD3 x CD28 x 4-1BB / Multispecific Antibody / OncologyAdvanced CancersPhase 1/2aactiveUS
- MDX2003MDX2003 / T-cell engager / Multispecific Antibody / OncologyLymphomaPhase 1activeUS
- ModeX COVID-19 Multispecific AntibodySARS-CoV-2 / Multispecific Antibody / Infectious DiseaseCOVID-19PreclinicalactiveUS
- ModeX Influenza Multispecific AntibodyInfluenza virus / Multispecific Antibody / Infectious DiseaseInfluenzaPreclinicalactiveUS
- Oral GLP-2 AgonistGLP-2 / Peptide / GastroenterologyShort Bowel SyndromePreclinicalactiveGlobal
Latest news12 items
All newsOPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Trial Start • Phase 1